

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE FIRST QUARTER ENDED 31 MARCH 2024

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 25 April 2024 (the “**Announcement**”) in relation to the report for the first quarter ended 31 March 2024 of China National Accord Medicines Corporation Ltd. (“**Sinopharm Accord**”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of Sinopharm Accord for the first quarter ended 31 March 2024 as set out in the Announcement.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD

Whether it has retroactive adjustment or restatement on previous accounting data or not

Yes No

Reasons for retroactive adjustment or restatement

Changes in accounting policies Correction of accounting errors

Merger of businesses under common control Other reasons

	The Reporting Period	Same period of last year		Changes of this period over the same period of last year (%)	
		Before adjustment	After adjustment		After adjustment
Revenue	19,090,480,767.90	18,686,817,786.50	18,686,817,786.50	2.16	
Net profit attributable to shareholders of the listed company	388,770,710.07	362,205,346.22	362,205,346.22	7.33	
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	369,722,432.36	351,786,799.59	351,786,799.59	5.10	
Net cash flow arising from operating activities	-634,145,768.90	209,985,468.33	209,985,468.33	-402.00	
Basic earnings per share (Yuan/Share)	0.70	0.85	0.65 (Note 2)	7.69	
Diluted earnings per share (Yuan/Share)	0.70	0.85	0.65 (Note 2)	7.69	
Weighted average return on net assets	2.21%	2.22%	2.22%	Decreased by 0.01 percentage point	

	At the end of the Reporting Period	At the end of last year		Changes of this period-end over the end of last year (%)
		Before adjustment	After adjustment	After adjustment
Total assets	51,524,997,265.01	47,571,094,779.26	47,571,094,779.26	8.31
Equity attributable to shareholders of listed company	17,803,579,439.13	17,414,808,729.06	17,414,808,729.06	2.23

Notes:

1. The Reporting Period refers to the three months ended 31 March 2024.

2. On 11 May 2023, the 2022 annual general meeting of Sinopharm Accord approved the "Proposal on Profit Distribution for the Year 2022 and Capitalization of Capital Reserve of Sinopharm Accord" (《國藥一致 2022 年度利潤分配及資本公積金轉增股本預案》), which agreed on the issuance of shares of Sinopharm Accord on the basis of 3 new shares for every 10 shares to all shareholders by way of capitalization of capital reserve, resulting in a total of 128,438,094 shares converted and issued. The equity distribution plan for A shares and B shares was completed on 1 June 2023 and 5 June 2023, respectively. In accordance with the relevant requirements of the Compilation Rules for Information Disclosure by Companies Offering Securities to the Public No. 9 – Computation and Disclosure of Return on Net Assets and Earnings per Share (《公開發行證券的公司信息披露編報規則第 9 號 – 淨資產收益率和每股收益的計算及披露》), Sinopharm Accord has recalculated the earnings per share for the comparative period on the basis of the total number of shares following the capitalization issue of shares. The basic earnings per share over the same period of last year were adjusted from RMB0.85 to RMB0.65.

INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION

In the first quarter of 2024, Sinopharm Accord focused on high-quality development as main line, grasping the annual work target of "improving efficiency and increasing benefits". Sinopharm Accord has achieved a revenue of RMB19.090 billion, representing a year-on-year increase of 2.16%; an operating profit of RMB0.544 billion, representing a year-on-year decrease of 5.61%; a total profit of RMB0.550 billion, representing a year-on-year decrease of 4.88%; a net profit of RMB0.446 billion, representing a year-on-year decrease of 3.19%, mainly because the sales volume of physical and chemical diagnostics, masks and other emergency supplies in the retail sector was relatively larger for the same period last year, and at the same time, some regions were affected by policies such as social security fund for pooling reimbursement, which led to a decline in performance for the current period; a net profit attributable to shareholders of the listed company of RMB0.389 billion, representing a year-on-year increase of 7.33%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of RMB0.370 billion, representing a year-on-year increase of 5.10%.

The distribution segment has achieved a revenue of RMB13.954 billion, representing a year-on-year increase of 6.77%, a net profit of RMB0.240 billion, representing a year-on-year increase of 10.07%. The retail segment has achieved a revenue of RMB5.387 billion, representing a year-on-year decrease of 8.30%; a net profit of RMB77 million, representing a year-on-year decrease of 49.94%.

By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC
25 April 2024

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the nonexecutive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.